Why Is REPLIGEN CORP (RGEN) Stock Up Today?

Repligen Corporation (RGEN) shares surged 10.90% to $145.34 in Monday trading, driven by a strong earnings report and raised full-year guidance. The biotechnology firm reported better-than-expected second-quarter results, including a 12% year-over-year revenue increase and an upward revision to its 2026 financial outlook. The stock's rally reflects investor optimism over the company's performance and strategic initiatives.

What Happened

Repligen reported second-quarter revenue of $204.1 million, a year-over-year increase of 12%. Non-GAAP earnings per share were $0.54, beating estimates by $0.09. The company also raised its full-year 2026 guidance, projecting adjusted EPS of $2.03 to $2.09, up from the previous range of $1.97 to $2.05. Revenue guidance was lifted to $813 million to $834 million for 2026. These results were highlighted in a July 28, 2026 earnings call and disclosed in a Form 8-K filed with the SEC. The company attributed the strong performance to 13% organic growth and the planned acquisition of BioLife Solutions, which is expected to expand its cell therapy business.

What The Data Shows

Repligen's stock closed at $145.34, a 10.90% increase from the prior session. The stock is currently trading within its 52-week range of $100.99 to $175.77. The company has a market capitalization of $7.4 billion and a P/E ratio of 144.0. Trailing twelve-month revenue grew 17.4%, and the firm maintains a net margin of 6.7%. Recent insider transactions include two sales by the CFO totaling $186,000. No unusual options activity or social media chatter was reported in the last 24 hours.

What To Watch

Repligen has not scheduled an upcoming earnings date. Investors should monitor the breadth of analyst coverage and any further developments regarding the BioLife Solutions acquisition.